Assessment of Annexin A2 as A Marker for Diagnosis of Hepatocellular Carcinoma in Compensated and Decompensated Hepatitis C Virus Treated Patients

Document Type : Original Article

Authors

1 Faculty of Medicine, Internal Medicine Department, Beni Suef University, Beni Suef, Egypt

2 Faculty of Medicine, Clinical Pathology Department, Beni Suef University, Beni Suef, Egypt

Abstract

Background: In the entire world, hepatocellular carcinoma (HCC) is considered as one of the most prevalent cancers. For earlier identification to enhance the clinical outcomes of HCC patients, more sensitive and specific indicators are required. Aim: To identify HCC, it is necessary to assess the annexin A2 levels in both compensated and decompensated HCV-treated patients. Methods: At the time of diagnosis and before starting treatment, blood specimens from 40 HCC individuals were taken and isolated plasma specimens were maintained at -80 °C until ANXA2 assays. The human ANXA2 enzyme-linked immunosorbent test (ELISA) kit was used to collect blood specimens from forty individuals with CHC but no HCC at the same duration as the blood specimens from HCC patients. Anti-ANXA2 antibodies were utilized as identification antibodies. Results: With a p-value of <0.001, the ANXA2 level sensitivity and specificity test demonstrated a statistically significant difference in the identification of HCC cases in both compensated and decompensate populations. In comparison to the decompensated group, the ANXA2 level's sensitivity in diagnosing HCC patients was 90% in the compensated status. Regarding AFP and ANXA2 levels, there was a statistically significant distinction (p <0.001) between the two study groups, with a greater mean among the HCC group. Conclusion: The combination of annexin A2 and AFP significantly boosts the diagnostic capability of this promising HCC diagnostic marker. Its serum concentration can be used as an effective, non-invasive tumour marker for HCC identification.

Keywords

Main Subjects

  1. Ibrahim, A. S., Khaled, H. M., Mikhail, N. N., Baraka, H., & Kamel, H. (2014). Cancer incidence in Egypt: results of the national population-based cancer registry program. Journal of cancer epidemiology, 2014.
  2. Blach, S., Zeuzem, S., Manns, M., Altraif, I., Duberg, A.-S., Muljono, D. H., Waked, I., Alavian, S. M., Lee, M.-H., & Negro, F. (2017). Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. The lancet Gastroenterology & hepatology, 2(3), 161-176.
  3. Valery, P. C., Laversanne, M., Clark, P. J., Petrick, J. L., McGlynn, K. A., & Bray, F. (2018). Projections of primary liver cancer to 2030 in 30 countries worldwide. Hepatology, 67(2), 600-611.
  4. Sun, Y., Gao, G., Cai, J., Wang, Y., Qu, X., He, L., Liu, F., Zhang, Y., Lin, K., & Ma, S. (2013). Annexin A2 is a discriminative serological candidate in early hepatocellular carcinoma. Carcinogenesis, 34(3), 595-604.
  5. Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011). Global cancer statistics. CA: a cancer journal for clinicians, 61(2), 69-90.
  6. Forner, A., Hessheimer, A. J., Real, M. I., & Bruix, J. (2006). Treatment of hepatocellular carcinoma. Critical reviews in oncology/hematology, 60(2), 89-98.
  7. Gerke, V., & Moss, S. (2002). LIDO/COMPLEXO. Annexins: From Structure to Function. Physiol. Rev, 82, 331-371.
  8. Sharma, M. R., Koltowski, L., Ownbey, R. T., Tuszynski, G. P., & Sharma, M. C. (2006). Angiogenesis-associated protein annexin II in breast cancer: selective expression in invasive breast cancer and contribution to tumor invasion and progression. Experimental and molecular pathology, 81(2), 146-156.
  9. Esposito, I., Penzel, R., Chaib‐Harrireche, M., Barcena, U., Bergmann, F., Riedl, S., Kayed, H., Giese, N., Kleeff, J., & Friess, H. (2006). Tenascin C and annexin II expression in the process of pancreatic carcinogenesis. The Journal of Pathology: A Journal of the Pathological Society of Great Britain and Ireland, 208(5), 673-685.
  10. Zhao, P., Zhang, W., Tang, J., Ma, X. K., Dai, J. Y., Li, Y., Jiang, J. L., Zhang, S. H., & Chen, Z. N. (2010). Annexin II promotes invasion and migration of human hepatocellular carcinoma cells in vitro via its interaction with HAb18G/CD147. Cancer science, 101(2), 387-395.
  11. Lokman, N. A., Ween, M. P., Oehler, M. K., & Ricciardelli, C. (2011). The role of annexin A2 in tumorigenesis and cancer progression. Cancer Microenvironment, 4, 199-208.
  12. Zhang, Q., Ye, Z., Yang, Q., He, X., Wang, H., & Zhao, Z. (2012). Upregulated expression of annexin II is a prognostic marker for patients with gastric cancer. World journal of surgical oncology, 10(1), 1-9.

Files

Share

How to cite

Statistics